`
`
` NDA 203341/S-016
`
`
`
`
`
`
`SUPPLEMENT APPROVAL
`
`
`
`
`
` PF Prism P.V.
`
` c/o Pfizer Inc.
`
` Attention: Bhanu Purohit, MS
` Global Regulatory Lead, Worldwide Safety and Regulatory
`
`
` 445 Eastern Point Road
`
` MS 8260-1118
` Groton, CT 06340
`
`
`
` Dear Ms. Purohit:
`
`
`
`
`Please refer to your supplemental new drug application (sNDA) dated
`
`
`
`February 19, 2019 and received February 19, 2019, and your amendments, submitted
`
`
`
`under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Bosulif
`
`(bosutinib) tablets.
`
`
`
`
`This Prior Approval supplemental new drug application provides for updates to the
`
`United States Prescribing Information Section 5.6 Embryo-Fetal Toxicity and Section
`
`
`
`8.1 Pregnancy based on the data from the Post-Natal Development Study.
`
`
`
`APPROVAL & LABELING
`
`
`
`
`We have completed our review of this application, as amended. It is approved, effective
`
`on the date of this letter, for use as recommended in the enclosed agreed-upon
`
`labeling.
`
`
`CONTENT OF LABELING
`
`As soon as possible, but no later than 14 days from the date of this letter, submit the
`
`
`
`
`content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using
`
`
`
`
`
`the FDA automated drug registration and listing system (eLIST), as described at
`
`
`
`
`FDA.gov.1 Content of labeling must be identical to the enclosed labeling (text for the
`
`Prescribing Information, Medication Guide.) with the addition of any labeling changes in
`
`
`
`pending “Changes Being Effected” (CBE) supplements, as well as annual reportable
`
`
` changes not included in the enclosed labeling.
`
`
`
`
` 1 http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
`
`
`
`Reference ID: 4477194
`
`

`

`
`
`
`
`
` NDA 203341/S-016
` Page 2
`
`
`
` Information on submitting SPL files using eList may be found in the guidance for
`
`
` industry SPL Standard for Content of Labeling Technical Qs and As.2
`
`
`
`
`The SPL will be accessible from publicly available labeling repositories.
`
`
`
`
`Also within 14 days, amend all pending supplemental applications that include labeling
`
`
`changes for this NDA, including CBE supplements for which FDA has not yet issued an
`
`
`
`
`action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word
`
`
`
`format, that includes the changes approved in this supplemental application, as well as
`
`annual reportable changes. To facilitate review of your submission(s), provide a
`
`
`highlighted or marked-up copy that shows all changes, as well as a clean Microsoft
`
`Word version. The marked-up copy should provide appropriate annotations, including
`
`
`
`supplement number(s) and annual report date(s).
`
`
`REQUIRED PEDIATRIC ASSESSMENTS
`
`Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for
`
`
`
`new active ingredients (which includes new salts and new fixed combinations), new
`
`
`indications, new dosage forms, new dosing regimens, or new routes of administration
`
`
`are required to contain an assessment of the safety and effectiveness of the product for
`
`
`
`the claimed indication in pediatric patients unless this requirement is waived, deferred,
`
`or inapplicable.
`
`
`Because none of these criteria apply to your application, you are exempt from this
`
`
`requirement.
`
`
`
`
`
`
`
`
`
` 2 We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance
` Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.
`
`
`
`
`
`U.S. Food and Drug Administration
`
`Silver Spring, MD 20993
`
`www.fda.gov
`
`
`
`
`
`Reference ID: 4477194
`
`

`

`
`
`
`
`
` NDA 203341/S-016
` Page 3
`
`
`
` PROMOTIONAL MATERIALS
`
` You may request advisory comments on proposed introductory advertising and
`
`
`
`
` promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter
` requesting advisory comments, (2) the proposed materials in draft or mock-up form with
`
`
`
`
` annotated references, and (3) the Prescribing Information to:
`
`
`
`OPDP Regulatory Project Manager
`
`Food and Drug Administration
`
`
`Center for Drug Evaluation and Research
`
`Office of Prescription Drug Promotion (OPDP)
`
`5901-B Ammendale Road
`
`Beltsville, MD 20705-1266
`
`
`
`
`
`Alternatively, you may submit a request for advisory comments electronically in eCTD
`
`
`
`
`format. For more information about submitting promotional materials in eCTD format,
`
`
`
`see the draft guidance for industry Providing Regulatory Submissions in Electronic and
`Non-Electronic Format-Promotional Labeling and Advertising Materials for Human
`
`Prescription Drugs.3
`
`
`
`
`You must submit final promotional materials and Prescribing Information, accompanied
`
`
`
`by a Form FDA 2253, at the time of initial dissemination or publication
`
`
`
`
`
`
`
`[21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.4 Information and
`
`
`
`
`
`Instructions for completing the form can be found at FDA.gov.5 For more information
`about submission of promotional materials to the Office of Prescription Drug Promotion
`
`
`(OPDP), see FDA.gov.6
`
`
`
`All promotional materials that include representations about your drug product must be
`
`promptly revised to be consistent with the labeling changes approved in this
`
`
`
`
`supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions
`
`
`
`in your promotional materials should include prominent disclosure of the important new
`
`
`safety information that appears in the revised labeling. Within 7 days of receipt of this
`
`
`
`
`letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the
`
`
`
`
`address above, by fax to 301-847-8444, or electronically in eCTD format. For more
`
`
`
`information about submitting promotional materials in eCTD format, see the draft
`
`
`guidance for industry Providing Regulatory Submissions in Electronic and Non-
`
`Electronic Format-Promotional Labeling and Advertising Materials for Human
`
`Prescription Drugs.
`
`
`
` 3 When final, this guidance will represent the FDA’s current thinking on this topic. For the most recent
` version of a guidance, check the FDA guidance web page at
`
` https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.
`
`4 http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
`
`
`
` 5 http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf
`
`
` 6 http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm
`
`U.S. Food and Drug Administration
`
`
`
`
`Silver Spring, MD 20993
`www.fda.gov
`
`
`
`
`
`
`Reference ID: 4477194
`
`

`

`
`
`
`
`
`
`
` NDA 203341/S-016
` Page 4
`
`
`
` REPORTING REQUIREMENTS
`
`
` We remind you that you must comply with reporting requirements for an approved NDA
`
` (21 CFR 314.80 and 314.81).
`
`
`
`
`
`If you have any questions, call Wanda Nguyen, Regulatory Project Manager, at (301)
`
`796-2808.
`
`
`
`
`
`
`Sincerely,
`
`
`
`{See appended electronic signature page}
`
`
`Albert Deisseroth, MD, PhD
`
`Supervisory Associate Division Director
`
`Division of Hematology Products
`
`Office of Hematology and Oncology Products
`
`
`Center for Drug Evaluation and Research
`
`
`
`ENCLOSURE:
`
`
`• Content of Labeling
`
`
`o Prescribing Information
`
`
`o Medication Guide
`
`
`
`
`
`
`
`
`
`U.S. Food and Drug Administration
`
`Silver Spring, MD 20993
`
`www.fda.gov
`
`
`
`Reference ID: 4477194
`
`

`

`Signature Page 1 of 1
`--------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically. Following this are manifestations of any and all
`electronic signatures for this electronic record.
`--------------------------------------------------------------------------------------------
`/s/
`------------------------------------------------------------
`
`ALBERT B DEISSEROTH
`08/14/2019 03:22:14 PM
`
`Reference ID: 4477194
`
`(b
`
`
`
`